Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 471-475

  Hernández Novoa, Beatriz ^a   Moreno, Ana ^a   Pérez Elías, María J ^a   Quereda, Carmen ^a   Dronda, Fernando ^a   Casado, José L ^a   Madrid Elena, Nadia ^a   Aguilar, Mónica ^a   Fumero, Emilio ^b   Moltó, José ^c   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

End stage liver disease; Integrase inhibitors; Plasma concentration

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INTERFERON; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MIXED INFECTION; MORNING DOSAGE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SEVERE HEPATIC IMPAIRMENT; TREATMENT DURATION; VIREMIA;

END-STAGE LIVER DISEASE; INTEGRASE INHIBITORS; PLASMA CONCENTRATION;

ADULT; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRROLIDINONES;

EID: 84892455811     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt386     Document Type: Article

References (27)

1. McCabe SM, Ma Q, Slish JC et al. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clin Pharmacokinet 2008; 47: 153-72.
2. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
3. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007; 14: 371-86.
4. Castellares C, Barreiro P, Martin-Carbonero L et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15: 165-72.
5. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
6. Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196: 670-6.
7. Cooper CL. An overview of HIV and chronic viral hepatitis co-infection. Dig Dis Sci 2008; 53: 899-904.
8. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
9. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
10. Rockstroh J, Teppler H, Zhao J et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012; 13: 127-31.
11. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-63.
12. Adedoyin A, Arns PA, Richards WO et al. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64: 8-17.
13. Becquemont L, Chazouilleres O, Serfaty L et al. Effect of interferon a-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71: 488-95.
14. George J, Liddle C, Murray M et al. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995; 49: 873-81.
15. Iwamoto M, Kassahun K, Troyer MD et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008; 48: 209-14.
16. Iwamoto M, Hanley WD, Petry AS et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother 2009; 53: 1747-52.
17. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
18. Poirier JM, Robidou P, Jaillon P. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 277-81.
19. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements byan interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
20. Barau C, Braun J, Vincent C et al. Pharmacokinetic study of raltegravir in HIV+ patients with end stage liver disease: LIVERAL ANRS 148 study. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, USA, 2013. Abstract 528. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
21. Grinsztejn B, Nguyen BY, KatlamaCet al. Safetyand efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) intreatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
22. Di Biagio A, Rosso R, Siccardi M et al. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother 2009; 64: 874-5.
23. Moreno A, Barcena R, Quereda C et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008; 22: 547-8.
24. Tricot L, Teicher E, Peytavin G et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-52.
25. Moreno A, Quereda C, Fortun J et al. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage. AIDS 2010; 24: 1231-3.
26. Moreno A, Quereda C, Montes M et al. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. J Acquir Immune Defic Syndr 2012; 61: e47-9.
27. Perez-Elias MJ, Morellon ML, Ortega E et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother 2009; 53: 5185-96.